Green Fresh Biotechnology Company Limited announced that, based on preliminary unaudited figures, it expects to post a net loss attributable to shareholders of between RMB1.00 million and RMB4.00 million for the six months ended 30 June 2026. This compares with a RMB12.07 million loss in the prior-year period, signalling a marked improvement in interim performance.\n\nManagement attributes the turnaround to higher sales volumes of carrageenan products, driven by a competitive pricing strategy that lifted both revenue and gross profit during the reporting period. Enhanced operating metrics also translated into stronger cash flows, with net operating cash inflow rising more than sevenfold versus the first half of 2025.\n\nThe figures are based on unaudited management accounts and remain subject to review by the Board and the company’s auditors. Green Fresh Biotechnology plans to release its full unaudited interim results before the end of August 2026.\n\nShareholders and prospective investors are advised to exercise caution when dealing in the company’s shares.